S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

OncLive® On Air - A podcast by OncLive® On Air

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

Visit the podcast's native language site